Perdoceo Education Faces Regulatory Headwinds Despite Strong 2025 Performance; USAHS Loan Restrictions Loom

summarizeSummary

Perdoceo Education reported strong 2025 financial results and announced a new $100 million stock repurchase program, but faces significant future headwinds from federal regulatory changes impacting student loan eligibility for key programs.

check_boxKey Events

• Strong 2025 Financial Performance

  Reported total revenue of $846.1 million (+24.2% YoY), net income of $159.9 million (+8.3% YoY), and diluted EPS of $2.42 (+10.5% YoY) for the year ended December 31, 2025. Total student enrollments increased 7.3% to 44,400.

• New $100 Million Stock Repurchase Program

  The Board of Directors approved a new $100.0 million common stock repurchase program on January 2, 2026, replacing the previous $75.0 million program. The company repurchased 4.1 million shares for $120.8 million in 2025.

• USAHS Letter of Credit Released

  The Department of Education notified USAHS on January 16, 2026, that it is no longer required to maintain its $20.5 million letter of credit, returning to the advanced method of payment and improving financial flexibility.

• Significant Regulatory Headwinds for Student Aid

  New federal legislation (Reconciliation Act) and negotiated rulemakings will eliminate Grad PLUS loans for new borrowers and impose lower borrowing limits on key USAHS health sciences programs (physical therapy, occupational therapy, speech-language pathology, nursing) starting July 1, 2026. This poses a material risk to future enrollment.

auto_awesomeAnalysis

This annual report provides comprehensive financial results for 2025, which were largely positive, but the market-moving impact is tempered by the concurrent 8-K filing. The most significant new information pertains to the evolving and challenging regulatory landscape for for-profit education. The detailed disclosure of the Reconciliation Act's impact, particularly the elimination of Grad PLUS loans for new borrowers and the reclassification of key USAHS health sciences programs, presents a material long-term risk to future enrollment and revenue. While the release of USAHS's $20.5 million letter of credit is a positive development for financial flexibility, it is overshadowed by these fundamental regulatory changes. Investors should closely monitor the company's ability to adapt its business model and mitigate the impact of reduced federal student aid availability, especially for its graduate health sciences programs.